Acasti Pharma Inc (ACST.OQ)
22 Mar 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|2016||Executive Chairman of the Board|
|2017||President, Chief Executive Officer, Director|
|2016||Chief Financial Officer|
|2010||Chief Operating Officer|
|Vice President- Clinical and Non-Clinical Affairs|
- BRIEF-Acasti Pharma Announces First Patient Randomized In Pivotal Trilogy Phase 3 Program Of CaPre
- BRIEF-Acasti Pharma Announces First Patient Randomized In Pivotal Trilogy Phase 3 Program Of CaPre In Severe Hypertriglyceridemia
- BRIEF-Acasti Pharma Files For Mixed Shelf Of Up To $50 Mln
- BRIEF-Acasti Pharma Q3 net Loss 2017 Was $0.40 Per Share
- BRIEF-Acasti Pharma Announces Issuance Of Common Shares In Payment Of Outstanding Interest Under Debentures